Therapeutic Options for the Single Pill Combination of Lisinopril, Amlodipine and Rosuvastatin: a Systematic Review
Open Access
- 8 September 2022
- journal article
- review article
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 18 (4), 480-488
- https://doi.org/10.20996/1819-6446-2022-08-13
Abstract
Aim. To evaluate the effect of taking a single pill combination of amlodipine, lisinopril and rosuvastatin on blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) in hypertensive patients with or without severe hypercholesterolemia. Material and methods. Articles published in Russian were selected for analysis. Six articles that met the criteria for inclusion in a systematic review were found by searching the eLibrary database for the keyword "equamer". The results of 5 observational clinical studies were presented in these articles. The effectiveness of the fixed combination of amlodipine, lisinopril and rosuvastatin was assessed mainly by changes in the level of systolic and diastolic blood pressure, the concentration of LDL cholesterol. In addition, the effects of fixed-dose amlodipine, lisinopril, and rosuvastatin on central aortic pressure and its increment index, as well as carotid-femoral pulse wave velocity, were studied in part of the studies. The effect of the fixed combination of amlodipine, lisinopril and rosuvastatin on blood pressure and LDL-C concentration, as well as on these additional indicators, in patients who had a coronavirus infection with severe lung damage was studied in one study. Results. Evidence from a systematic review demonstrates the efficacy of single pill combination amlodipine, lisinopril and rosuvastatin in reducing blood pressure and LDL-C in a wide range of patients with different baseline risk of developing cardiovascular complications and different baseline levels of blood pressure and LDL-C. Conclusion. The data obtained confirm the feasibility of more frequent prescription of the single pill combination of amlodipine, lisinopril and rosuvastatin in clinical practice for the treatment of hypertensive patients with high or moderate risk of developing cardiovascular diseases, including patients with concomitant hypercholesterolemia.Keywords
This publication has 30 references indexed in Scilit:
- Fixed‐dose vs free‐dose combinations for the management of hypertension—An analysis of 81 958 patientsThe Journal of Clinical Hypertension, 2018
- FIXED ETIOPATHOGENETIC COMBINATION OF DRUGS TO TREAT ARTERIAL HYPERTENSIONMedical Council, 2017
- Non-adherence to anti-hypertensive medication in low- and middle-income countries: a systematic review and meta-analysis of 92443 subjectsJournal of Human Hypertension, 2016
- Antiplatelet agents and anticoagulants for hypertensionEmergencias, 2011
- Pravastatin for Cardiovascular Event Primary Prevention in Patients With Mild-to-Moderate Hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) StudyHypertension, 2009
- 2007 ESH-ESC Practice Guidelines for the Management of Arterial HypertensionJournal of Hypertension, 2007
- Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes TrialEuropean Heart Journal, 2006
- Differential Impact of Blood Pressure–Lowering Drugs on Central Aortic Pressure and Clinical OutcomesCirculation, 2006
- 2003 European Society of Hypertension???European Society of Cardiology guidelines for the management of arterial hypertension*Journal of Hypertension, 2003
- Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialThe Lancet, 2003